OHDSI Home | Forums | Wiki | Github

Welcome to OHDSI! - Please introduce yourself

General
#171

Hello. My name is Neil Martinez. I am a Communications and Management Consultant facing the Life Sciences Industry. I have worked with industry professionals across the entire life cycle of development and commercialization for the past 20+ years. I am developing a common metadata model / methodology for life sciences companies and organizations that are making the leap from pre-commercial to commercialization.

A friend of mine that I knew from Bristol-Myers Squibb suggested I join this group. I managed a project he had to develop a web-based interface to patient claim data using commercially available SAS data sets. Since then I’ve managed the aggregation and analysis of US-based customer data for several clients driven by both CIA agreements and regulatory mandates.

I’ve also managed projects as diverse as migrating study plan data from/to Enterprise Project Management platforms, implementing programmatic controls to ensure FCPA compliance in purchasing systems, streamlining the procurement process (for professional services) from a business process perspective, and the redesign of Data Management and Analytics platforms across a $2.2B therapeutic area for a global pharma.

I live in Southern New Jersey, USA. I flunked out of Art School after a half year. I do not have a formal degree from anywhere but I have professional certifications from Microsoft (Dynamics CRM) and the Project Management Institute (PMP).

#172

Hi, I am Peter Heuschmann and I am chair of the Institute for Clinical Epidemiology and Biometry (ICE-B) at the medical faculty of the University of Würzburg.
The research activities of our institute are structured into three main research areas: clinical research; clinical epidemiology and health services research, setting the focus on actionable conditions. Using a wide variety of methods and data we are always interested in learning more about new applications and tools. So I welcome the opportunity to get familiar with tools provided by ODHSI.

#173

Hello,

My name is Jay Chatfield, and I am tenured Life Science Professional. During my 15-year tenure at Merck, I was a project manager in strategic alliances/business development and a science/strategy lead for a gram (+) antibiotic portfolio. I also had the privilege to collaborate with Premier, Inc., which is the largest healthcare alliance organization in the U.S. Working with Premier and, their alliance of health systems; I helped design biosimilar and vaccine population health initiatives and leveraged real-world data that identified unmet needs in recurrent C. difficile infection.

Currently, I am with Orexigen Therapeutics Inc., where I work on obesity population health initiatives and market access strategies for self-insured employers as well as integrated payer – provider health systems. We must understand specific needs of high-risk populations to identify cost-effective interventions, and I believe my experience in population health can support many needs throughout the OHDSI community. When not working I jump on the trampoline with my rambunctious seven-year-old twin boys. Truthfully, they jump on me!

#174

Hi I’m Heather Whitaker, stats lecturer at The Open University in the UK, and busy mum of two.

My work is in statistical methods for epidemiology, especially SCCS and self-controlled methods in general. I am especially interested in some of the methodological work that has been produced by ODHSI and would like to keep up to date with this part of your work, better understand your challenges and contribute if I can.

#175

Hi all, My name is Adib Zaman, a research scientist at the Regenstrief Center for Healthcare Engineering located at Purdue University, Indiana.
My interest is in the domain of integration of medical device data with EHRs, share-ability of research works (coding), and causal inference from observational data. I am working on multiple grant proposals in these domain with intensive care unit data. I am exploring opportunities to work for grant proposals with OHDSI as well as learning more about OHDSI.

Adib

#176

Hi All,

My Name is Nitish Kumar Jha working in JSS medical research India.
I am going to start ETL for a registry study for the first time.It would be really helpful if anyone can let me know how to start in this regard:
I have the raw datasets in SAS format and The CRF of the project ,
what else I need to start the process?
do I need some specific software like White Rabbit etc. ?

regards
Nitish Kumar Jha

ETL for a SAS-based registry study
#177

@nitishkjha:

Welcome to the family.

This is an introduction stream, so I took the liberty to try an answer to your question here.

#178

Hello All, my name is Colleen Erickson, working with the Evalytica team, and I am interested in keeping up-to-date with OHDSI tools and standards.

#179

Hello! I’m Adam Wright, a senior scientist at Brigham and Women’s Hospital (part of Partners HealthCare) in Boston and an associate professor at Harvard. I’m interested in clinical decision support and clinical data mining, especially related to detecting adverse drug events (ADEs). I’m interested in looking at ways we can detect both known ADEs (i.e. from the literature of experts) more accurately and also find previously-unknown patterns of ADEs. My research website is here: http://wrightlab.bwh.harvard.edu/. I’d love to collaborate with other OHDSI members on these kinds of studies, and also look at how we could map some of the data we have to the common data model.

#180

Hello. I am Michael Seungcheol Kang, an orthopaedic surgeon working in Asan Medical Center, Seoul, Korea. My subspecialty is pediatric orthopaedic surgery. I’m interested in various medical fields such as injury, sports, deformity, pain… And I and my research colleagues in our institute are currently converting the recent-5-years clinical data into the format of OMOP CDM version 5. I really want to collaborate with many other members.

#181

Hello Group,

I am Amit Kumar, a CDISC SDTM Mapping Specialist working in Cytel India. Right now I have got one OMOP CDM Project for ETL creation for an observational study.

We are generating DRUG_EXPOSURE Table in which I have some doubts ,

  1. Should we collect all Drug Exposure data captured in raw data like Prior Medication, Study Medication ??
  2. Most of Medication History data does not captures date what can we about that.?
    3.What are refill? can we keep them blank?
  3. How to generate drug_exposure_id ?

Kindly guide me as our team is doing it for first time.

DRUG_EXPOSURE conventions
#182

@Amit:

Welcome to the family!

This is an introduction stream, so it’s probably not a good idea to discuss detail here. I’ll start a new posting here.

But in general: For a full-fledged ETL conversion, you will run into a lot of questions like the ones above. It’s probably not a good idea to do this in the Forum piece-meal. What you need is a one-day work session. There are a few folks who will gladly do this for you, but you may have to compensate them a little bit.

#183

Hi all,

My name is Alice Porter and I work for a company called GrandCare which is a company that creates healthcare technology to assist the elderly and disabled people.

I am on the research team, which entails researching which features should be included/ will be most useful to the users, and has helped to successfully implement a monitoring system within the device.

The GrandCare system has recently come to the UK, so I am now based in Manchester helping to implement the right kind of features and changes to assist people over here and to see how their lifestyles and environments may require a different kind of accessibility/ usage.

Really keen to connect with like-minded individuals and professionals.

#184

This is Yu, Wenbo from China.

I was a biostatisician in Merck. Right now, I work for a innovation health company which focuses on intergrating electronic health records from hospitals in China. Right now, we have more than 40 third-class one-grade hospitals done. These hospitals are the summit in China.

I am a research manager in charge of converting the data into scientific findings with doctors.OHDSI is one of tools we are looking for the convertion. I am still learning more about it.

Furthermore, we are looking for collaboration from globalwise to help us accelerate the researches.

#185

My name is Gregg Hanold. My day job is as Chief Technology Officer, at Bellrock Intelligence. At Bellrock I am responsible for the technology, design, implementation and deployment decisions at Bellrock. Bellrock offers an Enterprise Intelligence Platform that provides decision support through actionable intelligence for the Healthcare industry through the Network Intelligence Rx solution. As part of our Architecture, we fuse the internal and institutional data sources from our clients. Our clinical team and advisers are exploring integration of the OMOP common data model and the use of OHDSI’s open-source tools as the foundation for our Clinical Data Model.

In terms of how I’d like to help the OHDSI community: My passion is in data sciences that can lead to better clinical outcomes through advanced analytical solutions. Supporting this community provides the collaboration vehicle and a common reference from which this can be achieved.

#186

Hey All,

My name is Roy Pardee and I’m a Data Architect at Kaiser Permanente of Washington (or as I prefer–KaPoW!) in the Health Research Institute. I’ve been very involved in the HCSRN’s Virtual Data Warehouse for a lot of years, and have a general interest in distributed health research.

My interest in the OMOP CDM was recently rekindled at the AMIA joint summit meeting last month. I’m hoping to learn how you all are using OMOP and its associated assets (especially the vocabulary!) to advance your research, and see what lessons I can learn to bring to my customers & collaborators.

1 Like
#187

Hi all,

My name is Hassan Chaudhury. I’m a co-founder and Chief Commercial Officer at Health iQ based in London’s Tech City. We’re an analytics agency with a heritage working in the NHS with real world observational data. We now use it primarily for pharmaceutical market access but also encompassing phase iii. I am involved in developing short courses at Imperial College London on data science and also the CSA for the IMI2 Big Data for Better Outcomes (BD4BO) project. My interest is in bringing interesting data science techniques to the data we have to make more informed clinical and commissioning decisions in the spirit of sustainability and care quality. OHDSI looks very interesting and I’m happy to help the community.

#188

Hello everyone,

I have just joined your journey on this forum!

My name is Shahed Iqbal. I am currently working in Daiichi Sankyo, Inc. as director of epidemiology in the clinical safety and pharmacovigilance department and leading the activities undertaken by the epidemiology team including conducting pre- and post-marketing studies using healthcare databases.

I am interested in getting involved in studies, participating in methods discussions, and in helping to write research papers.

When I am not working, I basically spend all of my time with my two daughters learning names and stories of all the princesses and their pets.

Hoping to have a meaningful involvement.

Best,

Shahed

#189

Hello everybody,

My name is Van, and I am an Statistical Programmer at the Oslo School of Nursing.

I am working on a Clinical trial study which is observational and we are trying to ETL through OMOP CDM.

I will need help regarding the same

Thank you.

#190

Hi all! I’m a researcher out of UC Denver | Anschutz (the medical campus). My current work is focused on analyzing APCD data and mapping these to the OMOP CDM. I’m excited to learn more from this community and contribute.

t